Cell therapy & immuno-oncology · Dendritic cell platform

Guardian Bio

A Boston biotech built a platform to grow a rare, potent dendritic cell from a cancer patient’s own stem cells and train it against that patient’s tumor. It reached preclinical proof of concept, then ran out of money. In November 2024 its founders put the company into hibernation.

A little cluster of dots

Days before their first Demo Day in the summer of 2022, Ananya Zutshi and Ricky Barrett joined a video call with the contract manufacturer running their first experiment. The screen showed a flow cytometry plot: a small cluster of dots. It was their first batch of manufactured cDC1s, the rare dendritic cell subtype the company had bet on. Not many cells, but clear and identifiable ones. It was the moment Guardian Bio went from an idea backed by literature to a company that could tell investors it had a working process.

The pitch: take stem cells from a cancer patient, differentiate them into conventional type 1 dendritic cells, or cDC1s, a subset the company calls Guard-cDC1s, train them against that patient’s own tumor, and reintroduce them. The company says Guard-cDC1s are capable of “restoring dysfunctional antigen presentation in late stage cancer patients.”

Why dendritic cells at all

Dendritic cells are not the immune system’s killers. They are its coordinators, deciding what the rest of the immune system should attack. Guardian Bio’s argument is that cancer disables this coordination early, and that most immunotherapies are fighting that disabled starting point rather than fixing it. A dendritic cell therapy developed a decade and a half earlier had reached the market with modest results, and the field mostly moved on. Guardian Bio bet a more precisely defined subset, cDC1s, would do better.

Two first-time founders and a third who lived the history

Ananya Zutshi studied biomedical engineering at Duke, then spent four years at the contract manufacturer Catalent before enrolling in Harvard’s joint MS/MBA in Engineering Sciences program. She became a Blavatnik Fellow in Life Science Entrepreneurship at Harvard Business School, the year she began developing the idea that became Guardian Bio. Her father had died of cancer shortly after she left Duke, before cell-based therapies existed for his disease.

Ricky Barrett had a different path into the same room: marine biology and scientific diving at Florida Atlantic University, then a PhD in immunology at the University of Central Florida, then a postdoctoral fellowship in cancer immunology at the University of Pennsylvania. He also built an audience of more than a quarter million followers making science content on TikTok and Instagram. A Nucleate connection introduced him to Zutshi in 2022.

A third co-founder came in for scientific weight: Karolina Palucka, a clinical oncologist and cancer immunologist whose lab pioneered dendritic cell vaccines for cancer and HIV patients, first at Baylor and later as director of the Jackson Laboratory Cancer Center. Her lab focuses on human immunology and experimental immunotherapy, understanding “how vaccines work and precisely defining the immune mechanisms that underpin successful vaccination.” She joined Guardian Bio as academic co-founder and chair of its scientific advisory board.

Yes in six days, then a long climb

Guardian Bio applied to Y Combinator after its batch deadline had already passed. An interview was scheduled the next day. Four hours later the founders had an answer: in, with $500,000 wired to the company, on the condition that both quit their jobs and be in San Francisco within six days for the Summer 2022 batch. The company was not yet incorporated when it was accepted.

What followed was a run of small, real wins during a bad biotech funding market. Guardian Bio won a 2022 LabCentral Ignite Golden Ticket, worth a year of free lab space and a $15,000 grant, and went through Creative Destruction Lab’s Advanced Therapies program, graduating in spring 2023. By 2024 the company said it had become the first team to generate functional cDC1s from late-stage cancer patient material, using samples obtained through Palucka’s clinical connections. It presented at the BIO International Convention, where its own listing said it was seeking a $3 million seed round for clinical trials planned for late 2024 or early 2025.

That round never closed. In summer 2023 a lead candidate investor passed, citing its investment committee’s unwillingness to back a cell therapy. The founders cut their own salaries by 70 percent to fund a pivotal humanized mouse study, which failed on the animal model itself. A $100,000 Massachusetts Life Sciences Center MassNextGen grant funded a second set of experiments that worked, showing the cells migrated to lymph nodes and kept their function. The company re-entered fundraising in April 2024, spoke with more than 300 investors, and in November 2024 convened a group of finalist funds on a joint call. An hour later, the answer came back no. With no runway left, the founders decided to stop.

What is proven, and what is still claimed

Read plainly, Guardian Bio is a preclinical-stage cell therapy platform that never reached the FDA, a registered trial, or a closed institutional round on the public record. What it did reach was a working manufacturing process for a hard-to-make cell type, validated through non-dilutive grants and an accelerator program, before the capital needed for the next step failed to arrive.

What to watch

• Whether the Palucka lab publishes the cDC1 data Guardian Bio generated, since the company says the science continues in academia even though the startup does not.
• Whether guardian-bio.com and the company’s Y Combinator listing remain live, or are eventually taken down, as signals of whether hibernation becomes permanent.
• Whether any later financing, sale of assets, or restart is announced for Guardian Bio or a successor entity.
• Whether a Form D or other SEC filing ever appears for Guardian Bio, which has not filed one as of this profile.

In their words

Related companies

• Forever Labs: Also in Therapeutics. An Ann Arbor company that cryopreserves an adult’s own stem cells against the possibility of a future therapy
• Kopra Bio: Also in Therapeutics. A UCSF spinout engineering a virus that turns brain tumor cells into local factories for an immune-stimulating protein
• Granza Bio: Also in Therapeutics. A San Francisco biotech trying to turn the immune system's own cell killing machinery into a programmable drug platform
• Asher Bio: Also in Therapeutics. A South San Francisco company rebuilding interleukin-2 so it reaches only the killer T cells that attack tumors

Sources

1. CompanyGuardian Bio company website, Purpose, Founders, Our Technology pagesguardian-bio.com · accessed Sep 25, 2026
2. CompanyGuardian Bio company listing and launch postY Combinator · accessed Sep 25, 2026
3. IndependentHBS Alumna Fighting Cancer with a Novel Cell TherapyHarvard Business School, Matt Goisman · Jan 26, 2024
4. IndependentAlumni profile: Ananya Zutshi, MS/MBA ’21Harvard John A. Paulson School of Engineering and Applied Sciences · Dec 18, 2023
5. IndependentLife on the Biotech Boats When the Tide Goes OutMedium, Ananya Zutshi and Ricky Barrett · Jun 12, 2025
6. IndependentKarolina Palucka, M.D., Ph.D., faculty pageThe Jackson Laboratory · accessed Sep 25, 2026
7. IndependentIgnite, 2023 Impact ReportLabCentral · 2024
8. IndependentLabCentral Ignite Launches Third Annual Golden Ticket ContestPR Newswire · May 15, 2023
9. IndependentGuardian Bio company pageCreative Destruction Lab · accessed Sep 25, 2026
10. CompanyGuardian Bio session listingBIO International Convention · 2024 program, accessed Sep 25, 2026
11. IndependentGuardian Bio company profileTracxn · accessed Sep 25, 2026
12. IndependentGuardian Bio: Funding, Team & InvestorsStartup Intros · accessed Sep 25, 2026
13. Public recordSEC EDGAR company search, “guardian bio”SEC · accessed Sep 25, 2026
14. Public recordFDA, NIH RePORTER, NSF Award Search and ClinicalTrials.gov, name searches for Guardian BioFederal databases · accessed Sep 25, 2026